Novo Nordisk bid for obesity-focused biotech firm could gazump Pfizer offer

Metsera viewed as a lucrative takeover target in part because of its promising research into weight-loss drugs Novo Nordisk has launched a surprise $9bn (£6.9bn) offer for US obesity-focused biotech firm Metsera that could gazump an existing bid from rival Pfizer, as the pharmaceutical giants fight for dominance in the growing weight-loss market.The bid comes weeks after Metsera agreed to a $7.3bn takeover from US firm Pfizer after Denmark’s Novo Nordisk, which owns the weight-loss drugs Ozempic and Wegovy, originally lost out in a competitive auction process. Continue reading...